Abbott Laboratories ABT reported first-quarter 2025 adjusted earnings per share (EPS) of $1.09, which beat the Zacks ...

Analysts are estimating that Abbott Laboratories will report an earnings per share (EPS) of $1.07. The market awaits Abbott ...

Abbott (NYSE: ABT) announced today that it launched a next-generation delivery system for its neuromodulation business.

A new U.S. Neurological Devices Market Report provides essential insights for CEOs, CFOs, product and marketing managers in the neurology and neurosurgery sectors, helping executives navigate ...

Abbott Park, Illinois Friday, April 4, 2025, 15:00 Hrs [IST] ...

Abbott today announced the launch of its neuromodulation business’ next-generation delivery system, which will be used to streamline the implantation process for electrodes used as part of its ...

Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ETCompany ParticipantsMike Comilla - VP, IRRobert Ford - Chairman ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.

Nexalin has received patent approval from the USPTO for its DIFS method for treating substance use disorders (SUD).